Der Hautarzt

, Volume 54, Issue 3, pp 237–241 | Cite as

Aktuelle Aspekte der topischen Psoriasisbehandlung

Leitthema
First Online:

Zusammenfassung

Neben den auch heute noch gebräuchlichen und häufig eingesetzten klassischen äußerlichen Behandlungskonzepten mit Dithranol oder Kortikosteroiden haben die topisch anwendbaren Vitamin-D3-Präparate oder Vitamin-D3-Analoga sowie topische Retinoide breite Verwendung gefunden. Kombinationen dieser neueren topischen Antipsoriatika sowohl untereinander als auch mit UV-Licht oder mit systemisch wirksamen Medikamenten haben oft eine größere therapeutische Effizienz als entsprechende Monotherapien. Besonders häufig wird in der Praxis bei Patienten mit leichter bis mittelschwerer Psoriasis die Kombination von Calcipotriol mit topischen Kortikosteroiden eingesetzt, die 2-mal täglich sequenziell, neuerdings auch 1-mal täglich in fixer Kombination angewendet werden kann. Auch bei schweren Formen der Psoriasis, die einer systemischen Behandlung bedürfen, ermöglicht eine zusätzliche wirksame topische Therapie ein besseres Langzeitmanagement.

Schlüsselwörter

Psoriasis Topische Therapie Kombinationstherapie Calcipotriol 

Abstract

Classical topical treatment regimens in psoriasis including dithranol and corticosteroids are widely used and have been supplemented in recent years by topical vitamin D preparations, by vitamin D analogues and topical retinoids.The combination of these preparations with each other, with UV light or with systemic drugs often lead to improved effectiveness and tolerability when compared with the respective monotherapy. In private offices, the combination of calcipotriol with various corticosteroids is very commonly prescribed for patients with mild to moderate psoriasis. This combination can be sequentially applied twice daily or -- in a newly introduced fixed preparation -- once daily. In severe psoriasis requiring systemic treatment a concomitant effective topical treatment regimen can greatly improve the overall longtime management in affected patients.

Keywords

Psoriasis Topical treatment Calcipotriol Combination regimens 
This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Braun-Falco O (1965) Zur Praxis der Psoriasis-Behandlung. Dtsch Med Wochenschr 90:1995–1998Google Scholar
  2. 2.
    Galewsky E (1916) Über Cignolin, ein Ersatzpräparat des Chrysarobins. Derm Wochenschr 62:113–115Google Scholar
  3. 3.
    Scholz A, Kadner H (1991) 75 Jahre Cignolin. Hautarzt 42:775–778Google Scholar
  4. 4.
    Swanbeck G, Liden S (1966) The inhibitory effect of dithranol (anthralin) on DNA synthesis. Acta Derm Venereol 46:228–230Google Scholar
  5. 5.
    Gerritsen MJP (1999) Dithranol. In: van de Kerkhof PCM (ed) Textbook of psoriasis. Blackwell Science Ltd., London, pp 160–178Google Scholar
  6. 6.
    Kemény L, Dobozy A (2001) Dithranol. In: Korting HC, Sterry W (Hrsg) Therapeutische Verfahren in der Dermatologie. Blackwell Wissenschafts-Verlag, Berlin Wien, S 209–213Google Scholar
  7. 7.
    Comaish S (1965) Ingram method of treating psoriasis. Arch Dermatol 92:56–58Google Scholar
  8. 8.
    Pion IA, Koenig KL, Lim HW (1995) Is dermatologic usage of coal tar carcinogenic? A review of the literature. Dermatol Surg 21: 227–231Google Scholar
  9. 9.
    Sulzberger MB, Witten VH (1952) The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 19:101–102Google Scholar
  10. 10.
    Barnes PJ, Adcock I (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 15:138–139Google Scholar
  11. 11.
    Gollnick HPM, Bonnekoh B (1999) Topical and systemic retinoids. In: van de Kerkhof PCM (ed) Textbook of psoriasis. Blackwell Science Ltd., London, pp 233–256Google Scholar
  12. 12.
    Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, Sefton J, Duvic M (1994) Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 30:581–590Google Scholar
  13. 13.
    Gollnick H, Menter A (1999) Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 140 [Suppl 54]:18–23Google Scholar
  14. 14.
    Lowe NJ (1999) Optimizing therapy: tazarotene in combination with phototherapy. Br J Dermatol 140 [Suppl 54]:8–11Google Scholar
  15. 15.
    Zügel U, Steinmeyer A, Giesen C, Asadullah K (2002) A novel immunosuppressive 1α,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity. J Invest Dermatol 119:1434–1442Google Scholar
  16. 16.
    Rigby WF, Waugh MG (1992) Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes. Arthritis Rheum 35:110–119Google Scholar
  17. 17.
    Hosomi J, Hosoi J, Abe E et al. (1983) Regulation of terminal differentiation of cultured mouse epidermal cells by 1alpha,25-dihydroxyvitamin D3. Endocrinology 113:1950–1957Google Scholar
  18. 18.
    Binderup L, Kragballe K (1992) Origin of the use of calcipotriol in psoriasis treatment. Rev Contemporary Pharmacotherapy 23:401–409Google Scholar
  19. 19.
    Fogh K, Kragballe K (1999) Vitamin D3 Analogues. In: van de Kerkhof PCM (ed) Textbook of psoriasis. Blackwell Science Ltd., London, pp 121–147Google Scholar
  20. 20.
    Langner A, Ashton P, van de Kerkhof PCM, Verjans H (1996) A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol 135:385–389Google Scholar
  21. 21.
    Van de Kerkhof PCM, Berth-Jones J, Griffiths CEM et al. (2002) Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 146:414–422Google Scholar
  22. 22.
    Kerscher M, Volkenandt M, Plewig G, Lehmann P (1993) Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB. Lancet 342:923Google Scholar
  23. 23.
    Molin L (1999) Topical calcipotriol combined with phototherapy for psoriasis. Dermatology 198:375–381Google Scholar
  24. 24.
    Lehmann B, Genehr T, Knuschke P et al. (2001) UVB-induced conversion of 7-dehydrocholesterol to 1alpha,25-dihydroxyvitamin D3 in an in vitro human skin equivalent model. J Invest Dermatol 117:1179–1185Google Scholar
  25. 25.
    Frappaz A, Thivolet J (1993) Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 3:351–354Google Scholar
  26. 26.
    Speight EL, Farr PM (1994) Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 130:79–82Google Scholar
  27. 27.
    Ortonne JP (1994) Psoriasis: new therapeutic modality by calcipotriol and betamethason dipropionate. Nouvelle Dermatologique 13:746–751Google Scholar
  28. 28.
    Wozel G (1994) Effektivität der Kombinationsbehandlung mit Calcipotriol und Fluocinolonacetonid im Psoriasis Plaque-Test. Akt Dermatol 20:155–158Google Scholar
  29. 29.
    Lebwohl M (1997) Topical application of calcipotriene and corticosteroids: combination regimes. J Am Acad Dermatol 37:S55–58Google Scholar
  30. 30.
    Ruzicka T, Lorenz B (1998) Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical theapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 138:254–258Google Scholar
  31. 31.
    Kragballe K, Barnes L, Hamberg KJ et al. (1998) Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 139:649–654Google Scholar
  32. 32.
    Douglas WS, Poulin Y, Decroix J et al. (2002) A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 82:131–135Google Scholar
  33. 33.
    Kaufmann R, Bibby AJ, Bissonnette R et al. (2002) A new calcipotriol/betamethasone dipropionate formulation (Daivobet™) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205:389–393Google Scholar
  34. 34.
    Guenther L, Cambazard F, van de Kerkhof PCM et al. (2002) Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 147:316–323Google Scholar
  35. 35.
    Katz HI (1997) Combined topical calcipotriene ointment 0,005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: Review of the literature and results of a survey sent to 100 dermatologists. J Am Acad Dermatol 37:S62–S68Google Scholar
  36. 36.
    Mrowietz U, Gräber M, Bräutigam M et al. (1998) The novel ascomycin derivative SDZ ASM 981 is effictive for psoriasis when used topically under occlusion. Br J Dermatol 139:992–996Google Scholar
  37. 37.
    Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI (1999) Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 141:103–107Google Scholar
  38. 38.
    Yamamoto T, Nishoioka K (2000) Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 80:451Google Scholar
  39. 39.
    Zonneveld IM, Rubins A, Jablonska S et al. (1998) Topical tacrolimus is not effective in chronic plaque psoriasis. Arch Dermatol 134:1101–1102Google Scholar
  40. 40.
    Erdogan M, Wright JR, McAlister VC (2002) Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol 146:964–967Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Klinik und Poliklinik für DermatologieUniversitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden
  2. 2.Klinik und Poliklinik für DermatologieUniversitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität DresdenDresden

Personalised recommendations